Literature DB >> 32643851

Patient- versus physician-reported relapses in multiple sclerosis: insights from a large observational study.

D Schriefer1, R Haase1, B Ettle2, T Ziemssen1.   

Abstract

BACKGROUND AND
PURPOSE: The patient's perspective is becoming increasingly important for endpoints in studies on multiple sclerosis. However, relapse data generated from the patient's perspective in combination with independent documentation by the physician are scarce. Our objective was to compare self-reported relapses by the patient to physician-documented relapses within a routine clinical practice setting of quarterly visits.
METHODS: Two-year data (n = 1921 patients) were extracted from two prospective, non-interventional, multicentre cohort studies in Germany. The number of relapses independently reported by patients and physicians was analysed. In addition, inter-rater reliability and measures of validity were evaluated. Patterns of associations were investigated in subgroup analysis of sociodemographic, clinical and patient-reported outcome measures.
RESULTS: Patients and physicians showed good overall agreement [κ = 0.78, 95% confidence interval (CI) 0.76-0.80]. Nevertheless, patients reported, on average, more relapses than physicians during follow-up (0.55 vs. 0.44; P < 0.001). Corresponding annualized relapse rates were 0.38 (95% CI 0.36-0.39) and 0.30 (95% CI 0.29-0.31), respectively. Differences between physicians and patients were particularly pronounced in patient groups with greater disability levels, decreased health-related quality of life or treatment satisfaction. The positive predictive value was 74.01% (95% CI 71.85-76.07), and the negative predictive value was 98.86% (95% CI 98.67-99.03).
CONCLUSION: Some disagreement on the occurrence of relapses appears in specific patient subgroups, where factors such as pseudo-relapses or confounding factors may have promoted over- or under-reporting.
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Entities:  

Keywords:  multiple sclerosis; patient-reported outcome; pseudo-relapse; relapse burden; reliability

Mesh:

Year:  2020        PMID: 32643851     DOI: 10.1111/ene.14432

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  4 in total

1.  Remote visits for people with multiple sclerosis during the COVID-19 pandemic in Austria: The TELE MS randomized controlled trial.

Authors:  Patrick Altmann; Fritz Leutmezer; Markus Ponleitner; Dominik Ivkic; Nik Krajnc; Paulus Stefan Rommer; Thomas Berger; Gabriel Bsteh
Journal:  Digit Health       Date:  2022-07-11

2.  COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies.

Authors:  Afagh Garjani; Rodden M Middleton; Rachael Hunter; Katherine A Tuite-Dalton; Alasdair Coles; Ruth Dobson; Martin Duddy; Stella Hughes; Owen R Pearson; David Rog; Emma C Tallantyre; Roshan das Nair; Richard Nicholas; Nikos Evangelou
Journal:  Mult Scler Relat Disord       Date:  2021-05-05       Impact factor: 4.808

3.  The German Multiple Sclerosis and Pregnancy Registry: rationale, objective, design, and first results.

Authors:  Sandra Thiel; Andrea I Ciplea; Ralf Gold; Kerstin Hellwig
Journal:  Ther Adv Neurol Disord       Date:  2021-11-22       Impact factor: 6.570

4.  Demographic Patterns of MS Patients Using BRISA: An MS-Specific App in Germany.

Authors:  Preetha Balakrishnan; Jannis Groenberg; Elizabeth Jacyshyn-Owen; Markus Eberl; Benjamin Friedrich; Natalie Joschko; Tjalf Ziemssen
Journal:  J Pers Med       Date:  2022-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.